BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: D'Amelio P, Grimaldi A, Di Bella S, Tamone C, Brianza SZ, Ravazzoli MG, Bernabei P, Cristofaro MA, Pescarmona GP, Isaia G. Risedronate reduces osteoclast precursors and cytokine production in postmenopausal osteoporotic women. J Bone Miner Res 2008;23:373-9. [PMID: 17967134 DOI: 10.1359/jbmr.071031] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 3.1] [Reference Citation Analysis]
Number Citing Articles
1 Muto A, Mizoguchi T, Udagawa N, Ito S, Kawahara I, Abiko Y, Arai A, Harada S, Kobayashi Y, Nakamichi Y, Penninger JM, Noguchi T, Takahashi N. Lineage-committed osteoclast precursors circulate in blood and settle down into bone. J Bone Miner Res 2011;26:2978-90. [DOI: 10.1002/jbmr.490] [Cited by in Crossref: 69] [Cited by in F6Publishing: 59] [Article Influence: 6.3] [Reference Citation Analysis]
2 Kyrgidis A, Koloutsos G, Vahtsevanos K. Treatment protocols of bisphosphonate-related osteonecrosis of the jaws. Head Neck 2009;31:1112-3. [DOI: 10.1002/hed.21148] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
3 Tzschentke TM. Pharmacology of bisphosphonates in pain. Br J Pharmacol 2021;178:1973-94. [PMID: 31347149 DOI: 10.1111/bph.14799] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
4 de Vries TJ, El Bakkali I, Kamradt T, Schett G, Jansen IDC, D'Amelio P. What Are the Peripheral Blood Determinants for Increased Osteoclast Formation in the Various Inflammatory Diseases Associated With Bone Loss? Front Immunol 2019;10:505. [PMID: 30941138 DOI: 10.3389/fimmu.2019.00505] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 7.7] [Reference Citation Analysis]
5 de Vries TJ, Everts V. Osteoclast Formation from Peripheral Blood of Patients with Bone-lytic Diseases. Clinic Rev Bone Miner Metab 2009;7:285-92. [DOI: 10.1007/s12018-009-9057-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
6 Lim SS, Lee B, Kim IS, Hwang SJ. Differential modulation of zoledronate and etidronate in osseous healing of an extracted socket and tibia defect. Oral Surg Oral Med Oral Pathol Oral Radiol 2017;123:8-19. [PMID: 27727104 DOI: 10.1016/j.oooo.2016.08.009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
7 Pandey A, Misra P, Khan MP, Swarnkar G, Tewari MC, Bhambhani S, Trivedi R, Chattopadhyay N, Trivedi PK. Co-expression of Arabidopsis transcription factor, AtMYB12, and soybean isoflavone synthase, GmIFS1, genes in tobacco leads to enhanced biosynthesis of isoflavones and flavonols resulting in osteoprotective activity. Plant Biotechnol J 2014;12:69-80. [PMID: 24102754 DOI: 10.1111/pbi.12118] [Cited by in Crossref: 50] [Cited by in F6Publishing: 42] [Article Influence: 5.6] [Reference Citation Analysis]
8 Forte L, Sarda S, Torricelli P, Combes C, Brouillet F, Marsan O, Salamanna F, Fini M, Boanini E, Bigi A. Multifunctionalization Modulates Hydroxyapatite Surface Interaction with Bisphosphonate: Antiosteoporotic and Antioxidative Stress Materials. ACS Biomater Sci Eng 2019;5:3429-39. [DOI: 10.1021/acsbiomaterials.9b00795] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
9 Lin X, Yu H, Zhao C, Qian Y, Hong D, Huang K, Mo J, Qin A, Fang X, Fan S. The Peripheral Blood Mononuclear Cell Count Is Associated With Bone Health in Elderly Men: A Cross-Sectional Population-Based Study. Medicine (Baltimore) 2016;95:e3357. [PMID: 27082593 DOI: 10.1097/MD.0000000000003357] [Cited by in Crossref: 3] [Article Influence: 0.5] [Reference Citation Analysis]
10 Vijayan V, Khandelwal M, Manglani K, Gupta S, Surolia A. Methionine down-regulates TLR4/MyD88/NF-κB signalling in osteoclast precursors to reduce bone loss during osteoporosis. Br J Pharmacol 2014;171:107-21. [PMID: 24111943 DOI: 10.1111/bph.12434] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
11 Kanazawa I, Yamaguchi T, Hayashi K, Takase H, Shimizu T, Sugimoto T. Effects of treatment with risedronate and alfacalcidol on progression of atherosclerosis in postmenopausal women with type 2 diabetes mellitus accompanied with osteoporosis. Am J Med Sci 2010;339:519-24. [PMID: 20400887 DOI: 10.1097/MAJ.0b013e3181db6dfe] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
12 Qiu S, Divine GW, Palnitkar S, Kulkarni P, Guthrie TS, Honasoge M, Rao SD. Bone Structure and Turnover Status in Postmenopausal Women with Atypical Femur Fracture After Prolonged Bisphosphonate Therapy. Calcif Tissue Int 2017;100:235-43. [PMID: 28013363 DOI: 10.1007/s00223-016-0223-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
13 Wang L, Guo TZ, Hou S, Wei T, Li WW, Shi X, Clark JD, Kingery WS. Bisphosphonates Inhibit Pain, Bone Loss, and Inflammation in a Rat Tibia Fracture Model of Complex Regional Pain Syndrome. Anesth Analg. 2016;123:1033-1045. [PMID: 27636578 DOI: 10.1213/ane.0000000000001518] [Cited by in Crossref: 27] [Cited by in F6Publishing: 17] [Article Influence: 5.4] [Reference Citation Analysis]
14 Koek WNH, van der Eerden BCJ, Alves RDAM, van Driel M, Schreuders-Koedam M, Zillikens MC, van Leeuwen JPTM. Osteoclastogenic capacity of peripheral blood mononuclear cells is not different between women with and without osteoporosis. Bone 2017;95:108-14. [PMID: 27845263 DOI: 10.1016/j.bone.2016.11.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
15 Eslami B, Zhou S, Van Eekeren I, LeBoff MS, Glowacki J. Reduced osteoclastogenesis and RANKL expression in marrow from women taking alendronate. Calcif Tissue Int 2011;88:272-80. [PMID: 21327765 DOI: 10.1007/s00223-011-9473-5] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
16 Bowsher RR, Sailstad JM. Insights in the application of research-grade diagnostic kits for biomarker assessments in support of clinical drug development: bioanalysis of circulating concentrations of soluble receptor activator of nuclear factor kappaB ligand. J Pharm Biomed Anal 2008;48:1282-9. [PMID: 18977625 DOI: 10.1016/j.jpba.2008.09.026] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
17 Bethel M, Bůžková P, Fink HA, Robbins JA, Cauley JA, Lee J, Barzilay JI, Jalal DI, Carbone LD. Soluble CD14 and fracture risk. Osteoporos Int 2016;27:1755-63. [DOI: 10.1007/s00198-015-3439-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
18 Yu YY, Lieu S, Hu D, Miclau T, Colnot C. Site specific effects of zoledronic acid during tibial and mandibular fracture repair. PLoS One 2012;7:e31771. [PMID: 22359627 DOI: 10.1371/journal.pone.0031771] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 2.8] [Reference Citation Analysis]
19 Rothe R, Schulze S, Neuber C, Hauser S, Rammelt S, Pietzsch J. Adjuvant drug-assisted bone healing: Part III - Further strategies for local and systemic modulation. Clin Hemorheol Microcirc 2019;73:439-88. [PMID: 31177207 DOI: 10.3233/CH-199104] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
20 D’Amelio P, Grimaldi A, Di Bella S, Brianza SZ, Cristofaro MA, Tamone C, Giribaldi G, Ulliers D, Pescarmona GP, Isaia G. Estrogen deficiency increases osteoclastogenesis up-regulating T cells activity: a key mechanism in osteoporosis. Bone. 2008;43:92-100. [PMID: 18407820 DOI: 10.1016/j.bone.2008.02.017] [Cited by in Crossref: 207] [Cited by in F6Publishing: 194] [Article Influence: 14.8] [Reference Citation Analysis]
21 Kyrgidis A, Triaridis S, Vahtsevanos K, Antoniades K. Osteonecrosis of the jaw and bisphosphonate use in breast cancer patients. Expert Review of Anticancer Therapy 2014;9:1125-34. [DOI: 10.1586/era.09.74] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
22 Karadag-saygi E, Akyuz G, Bizargity P, Ay P. The effect of risedronate treatment on serum osteoprotegerin and bone marker levels in postmenopausal women with osteoporosis. Gynecological Endocrinology 2011;27:1033-6. [DOI: 10.3109/09513590.2011.579657] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
23 Stuss M, Rieske P, Cegłowska A, Stêpień-Kłos W, Liberski PP, Brzeziańska E, Sewerynek E. Assessment of OPG/RANK/RANKL gene expression levels in peripheral blood mononuclear cells (PBMC) after treatment with strontium ranelate and ibandronate in patients with postmenopausal osteoporosis. J Clin Endocrinol Metab 2013;98:E1007-11. [PMID: 23543663 DOI: 10.1210/jc.2012-3885] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
24 Kawate H, Ohnaka K, Adachi M, Kono S, Ikematsu H, Matsuo H, Higuchi K, Takayama T, Takayanagi R. Alendronate improves QOL of postmenopausal women with osteoporosis. Clin Interv Aging 2010;5:123-31. [PMID: 20458350 DOI: 10.2147/cia.s9696] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
25 Henriksen K, Bollerslev J, Everts V, Karsdal MA. Osteoclast activity and subtypes as a function of physiology and pathology--implications for future treatments of osteoporosis. Endocr Rev 2011;32:31-63. [PMID: 20851921 DOI: 10.1210/er.2010-0006] [Cited by in Crossref: 138] [Cited by in F6Publishing: 123] [Article Influence: 11.5] [Reference Citation Analysis]
26 Naylor KE, Bradburn M, Paggiosi MA, Gossiel F, Peel NFA, Mccloskey EV, Walsh JS, Eastell R. Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density. Osteoporos Int 2018;29:1407-17. [DOI: 10.1007/s00198-018-4460-6] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 5.8] [Reference Citation Analysis]
27 Kramer JM, Fantasia JE. Bisphosphonates and Osteonecrosis of the Jaws: A Review of Clinical Features and the Drug Effect on Oral Soft Tissues. Clinic Rev Bone Miner Metab 2011;9:38-46. [DOI: 10.1007/s12018-011-9083-9] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
28 Kyrgidis A, Triaridis S, Antoniades K. Effects of bisphosphonates on keratinocytes and fibroblasts having a role in the development of osteonecrosis of the jaw. Bioscience Hypotheses 2009;2:153-9. [DOI: 10.1016/j.bihy.2009.02.005] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
29 Jeong HM, Jin Y, Choi Y, Chung JO, Cho DH, Chung MY, Civitelli R, Chung DJ, Lee KY. Risedronate increases osteoblastic differentiation and function through connexin43. Biochemical and Biophysical Research Communications 2013;432:152-6. [DOI: 10.1016/j.bbrc.2013.01.068] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
30 D'Amelio P, Tamone C, Sassi F, D'Amico L, Roato I, Patanè S, Ravazzoli M, Veneziano L, Ferracini R, Pescarmona GP, Isaia GC. Teriparatide increases the maturation of circulating osteoblast precursors. Osteoporos Int 2012;23:1245-53. [PMID: 21617993 DOI: 10.1007/s00198-011-1666-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
31 Wells GA, Hsieh SC, Zheng C, Peterson J, Tugwell P, Liu W. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2022;5:CD004523. [PMID: 35502787 DOI: 10.1002/14651858.CD004523.pub4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 D’amelio P. The immune system and postmenopausal osteoporosis. Immunological Investigations 2013;42:544-54. [DOI: 10.3109/08820139.2013.822764] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
33 Petitprez V, Royer B, Desoutter J, Guiheneuf E, Rigolle A, Marolleau JP, Kamel S, Guillaume N. CD14+ CD16+ monocytes rather than CD14+ CD51/61+ monocytes are a potential cytological marker of circulating osteoclast precursors in multiple myeloma. A preliminary study. Int J Lab Hematol 2015;37:29-35. [PMID: 24661393 DOI: 10.1111/ijlh.12216] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
34 D'Amelio P, Cristofaro MA, Grimaldi A, Ravazzoli M, Pluviano F, Grosso E, Pescarmona GP, Isaia GC. The role of circulating bone cell precursors in fracture healing. Calcif Tissue Int 2010;86:463-9. [PMID: 20390407 DOI: 10.1007/s00223-010-9362-3] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 2.4] [Reference Citation Analysis]
35 Kim BB, Ko Y, Park JB. Effects of risedronate on the morphology and viability of gingiva-derived mesenchymal stem cells. Biomed Rep 2015;3:845-8. [PMID: 26623028 DOI: 10.3892/br.2015.520] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
36 D’amelio P, Grimaldi A, Cristofaro MA, Ravazzoli M, Molinatti PA, Pescarmona GP, Isaia GC. Alendronate reduces osteoclast precursors in osteoporosis. Osteoporos Int 2010;21:1741-50. [DOI: 10.1007/s00198-009-1129-1] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 2.2] [Reference Citation Analysis]
37 Dalbeth N, Pool B, Stewart A, Horne A, House ME, Cornish J, Reid IR. No Reduction in Circulating Preosteoclasts 18 Months after Treatment with Zoledronate: Analysis from a Randomized Placebo Controlled Trial. Calcif Tissue Int 2013;92:1-5. [DOI: 10.1007/s00223-012-9654-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
38 Shimano RC, Macedo AP, Falcai MJ, Ervolino E, Shimano AC, Issa JP. Biomechanical and microstructural benefits of physical exercise associated with risedronate in bones of ovariectomized rats. Microsc Res Tech 2014;77:431-8. [PMID: 24692117 DOI: 10.1002/jemt.22363] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]